TACE FOR COLORECTAL
LIVER METASTASES
DEBIRI — irinotecan-loaded drug-eluting bead TACE — delivers regional irinotecan directly to colorectal liver metastases, bypassing the systemic dose limitations that prevent full efficacy of IV irinotecan. Combined with FOLFOX, it has demonstrated significant survival benefit over chemotherapy alone in liver-dominant CRLM.
analyticsAt a Glance
- check_circleEPOCH Phase III trial: DEBIRI + FOLFOX improved median OS from 15.3 to 22.0 months in liver-dominant CRLM vs FOLFOX alone
- check_circleDEBIRI uses irinotecan-loaded DC Bead or similar microspheres — distinct from HCC TACE which uses doxorubicin
- check_circlePatient selection: liver-dominant disease (≥80% tumour burden in liver); performance status ECOG 0–1; no significant extrahepatic progression
- check_circleWidely available at Chinese interventional oncology centres — DEBIRI is part of routine practice at high-volume hepatic oncology programmes
Why TACE for Colorectal Liver Metastases? The DEBIRI Rationale
Colorectal liver metastases (CRLM) derive 80–90% of their blood supply from the hepatic artery — the same vascular biology that makes HCC targetable with TACE. Systemic irinotecan is limited by dose-related systemic toxicity (diarrhoea, neutropaenia). Delivering irinotecan intra-arterially via drug-eluting beads (DEBIRI) achieves hepatic tumour drug concentrations 10–100× higher than systemic IV delivery, while reducing systemic exposure by 40–60% — the pharmacokinetic basis for DEBIRI's therapeutic advantage.
“CRLM and HCC share their vascular dependence on the hepatic artery. DEBIRI exploits the same biology that makes conventional doxorubicin TACE work for HCC — but the drug is changed from doxorubicin to irinotecan, reflecting the chemosensitivity profile of colorectal cancer.”
How DEBIRI Differs from Doxorubicin DEB-TACE for HCC
The microsphere platform is the same (DC Bead or LifePearl loaded with the relevant drug), but the drug loaded is irinotecan rather than doxorubicin — reflecting colorectal cancer's established sensitivity to irinotecan (the I in FOLFIRI/XELIRI). The loading protocol, release kinetics, and procedural technique are identical to HCC DEB-TACE; the clinical context and drug formulation distinguish the two applications.
The Combination Strategy: DEBIRI + Systemic FOLFOX
DEBIRI addresses the hepatic metastatic burden locally — reducing liver tumour volume and potentially converting some patients to resection. FOLFOX (or FOLFIRI/FOLFOXIRI) addresses systemic disease — micrometastatic disease and extrahepatic deposits invisible on imaging. The EPOCH trial tested this combination specifically: DEBIRI delivered every 3 weeks alternating with FOLFOX cycles, demonstrating significant OS benefit over FOLFOX alone in liver-dominant disease.
EPOCH Trial Results: DEBIRI + FOLFOX vs FOLFOX Alone
The EPOCH trial is the pivotal Phase III randomised controlled trial establishing DEBIRI combined with FOLFOX as a superior strategy to FOLFOX alone in patients with liver-dominant CRLM who have received prior systemic therapy.
EPOCH Trial: DEBIRI + FOLFOX vs FOLFOX Alone for Liver-Dominant CRLM
Source: Fiorentini G et al., Future Oncol 2017; updated analysis Fiorentini 2020. 74 patients. Liver-dominant CRC with ≥80% tumour burden in liver; ≥1 prior chemotherapy line.
- Median OS: DEBIRI + FOLFOX22.0 mo
- Median OS: FOLFOX alone15.3 mo
- Median PFS: DEBIRI + FOLFOX7.0 mo
- Median PFS: FOLFOX alone4.0 mo
- ORR: DEBIRI + FOLFOX68.8%
- ORR: FOLFOX alone20.0%
Patient Selection for DEBIRI-TACE in CRLM
DEBIRI-TACE has the most evidence in liver-dominant CRLM — selection criteria guide which patients are most likely to benefit.
| Criterion | Favourable for DEBIRI-TACE | Less Suitable / Caution |
|---|---|---|
| Hepatic tumour burden | Liver-dominant disease — ≥80% of total tumour burden in the liver; limited or stable extrahepatic disease | Rapidly progressive extrahepatic disease: DEBIRI will not control systemic disease; systemic therapy alone preferred |
| Prior lines of chemotherapy | 1–3 prior lines including FOLFIRI or FOLFOX-based regimens; irinotecan-naive patients may benefit most | Refractory to all standard agents including irinotecan AND oxaliplatin — limited benefit when all lines exhausted |
| Number of liver lesions | Bilobar multiple metastases amenable to lobar or segmental DEBIRI; up to 25–30% liver involvement | >50% liver replacement by tumour: risk of decompensation; inadequate functional liver remnant for sequential DEBIRI sessions |
| Prior hepatic surgery | Prior hepatic resection is not a contraindication | Prior hepatic arterial infusion pump placement may alter arterial anatomy — discuss with IR team |
| RAS/BRAF status | Does not determine DEBIRI eligibility — DEBIRI delivers irinotecan regardless of RAS status | BRAF V600E: poor prognosis regardless; DEBIRI remains appropriate if liver-dominant but outcomes worse |
| Performance status | ECOG 0–1 | ECOG 2+: increased toxicity risk; poor tolerance of combined DEBIRI + FOLFOX |
| Liver function | Normal or mildly elevated LFTs; no significant biliary obstruction | Significant biliary involvement from metastases: biliary complication risk — consider antibiotics and limited embolisation |
DEBIRI + FOLFOX vs Systemic-Only Approaches for Liver-Dominant CRLM
Understanding what DEBIRI adds — and what it does not replace — helps patients make informed decisions about this combination approach.
What DEBIRI + Systemic Adds
- Superior hepatic response rate (69% vs 20%)DEBIRI achieves dramatically higher hepatic objective response rates — a direct consequence of regional drug concentrations that systemic IV irinotecan cannot match.
- 6.7-month median OS improvement (EPOCH)The OS benefit in the EPOCH trial is clinically meaningful and statistically significant in a population with limited treatment options after 1–2 prior lines.
- Potential conversion to hepatic resectionMajor hepatic responses to DEBIRI — particularly when combined with FOLFOX — can downstage initially unresectable liver disease to resectable, offering a curative pathway.
- Reduced systemic irinotecan toxicityRegional delivery reduces systemic irinotecan Cmax by 40–60% — allowing higher effective hepatic doses with less systemic diarrhoea and neutropaenia than IV irinotecan at equivalent doses.
What DEBIRI Does Not Replace
- Extrahepatic disease controlDEBIRI has no mechanism to address lymph node, pulmonary, peritoneal, or bone metastases — systemic chemotherapy remains essential to address disease beyond the liver.
- Anti-EGFR or anti-VEGF targeted therapy decisionsDEBIRI is added to a systemic regimen — the decision about anti-EGFR (cetuximab, panitumumab) for RAS wild-type disease and anti-VEGF (bevacizumab) for RAS-mutant disease remains unchanged.
- Prevention of new hepatic lesion formationLike HCC TACE, DEBIRI treats existing lesions but does not prevent formation of new hepatic metastases from circulating tumour cells — systemic treatment continuity is required.
DEBIRI for CRLM: Key Numbers
Reference figures from the EPOCH trial and supporting series.
- 22.0 moMedian OS: DEBIRI + FOLFOX in liver-dominant CRLM (EPOCH trial)Versus 15.3 months with FOLFOX alone — a 6.7-month median OS improvement in a population with previously limited options.
- 68.8%Objective response rate: DEBIRI + FOLFOX (EPOCH trial)Versus 20% with FOLFOX alone — a striking 3.4× difference in hepatic response rate demonstrating the pharmacokinetic advantage of regional delivery.
- 80%Minimum liver tumour burden (% of total) for DEBIRI-TACE eligibilityThe liver-dominant threshold — DEBIRI provides the most benefit when the liver is the primary site of disease burden.
- 10–15%Conversion to hepatic resection rate with major DEBIRI responseA meaningful proportion of initially unresectable CRLM patients achieve resectable disease after DEBIRI — offering a curative outcome in what was an incurable presentation.
More from the TACE Resource Library
Continue exploring liver-directed therapy options for colorectal and other liver malignancies.
- What Is TACE? A Patient Introduction to Liver Cancer Embolisation
- TACE + RFA and TACE + MWA for HCC 3–7 cm
- cTACE vs DEB-TACE: Which Technique Is Right for Your HCC?
- Cryoablation for Liver Tumours: HCC and Metastases
- TACE Therapy — Complete Treatment Guide
- HIPEC for Colorectal Cancer Peritoneal Metastases
Frequently Asked Questions
Common questions from colorectal cancer patients with liver metastases exploring DEBIRI-TACE.
About DEBIRI for Colorectal Liver Metastases
I have lung metastases as well as liver metastases from my colorectal cancer — can I still have DEBIRI?
Having extrahepatic disease — including lung metastases — does not automatically exclude you from DEBIRI-TACE, but it is an important consideration. The EPOCH trial enrolled patients with liver-dominant disease (≥80% of tumour burden in the liver) — patients with rapidly progressive or bulky extrahepatic disease were not the primary population. If your lung metastases are small, stable, or responding to systemic chemotherapy, and your liver disease is the dominant clinical challenge, DEBIRI remains potentially appropriate as a regional intensification strategy alongside continuing systemic therapy. If lung metastases are progressing rapidly or represent the greater clinical burden, systemic therapy optimisation is the priority rather than liver-directed treatment. This is a case-by-case decision best made at a multidisciplinary oncology team review.
I have already received FOLFIRI (irinotecan-based chemotherapy) — will irinotecan-loaded DEBIRI still work?
Prior IV irinotecan therapy does not preclude DEBIRI-TACE, but it raises a legitimate question about irinotecan resistance. Colorectal metastases that have progressed through FOLFIRI may have developed some degree of irinotecan resistance — in which case DEBIRI would deliver high concentrations of a drug the tumour is already partly resistant to. However, the hepatic drug concentrations achieved by DEBIRI (10–100× higher than systemic IV delivery) may overcome resistance mechanisms that limit systemic irinotecan efficacy. Patients with prior irinotecan exposure in the EPOCH trial still showed benefit — though patients with first exposure show higher response rates. Prior FOLFIRI is not an absolute exclusion; it is a factor that should be discussed at your hepatobiliary MDT when considering DEBIRI.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Liver-Dominant Colorectal Metastases? DEBIRI May Help.
CancerFax reviews your CRLM burden, prior chemotherapy lines, KRAS/BRAF/RAS status, and performance status to assess whether DEBIRI-TACE is appropriate — and connects you with specialist interventional oncology teams in China performing DEBIRI routinely.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.